HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
0.400
0.00 (0.00%)
Apr 29, 2026, 9:47 AM EDT - Market open
HCW Biologics Revenue
In the year 2025, HCW Biologics had annual revenue of $54.23K, down -97.89%. HCW Biologics had revenue of $27.01K in the quarter ending December 31, 2025, a decrease of -93.16%.
Revenue (ttm)
$54.23K
Revenue Growth
-97.89%
P/S Ratio
49.67
Revenue / Employee
$1,506
Employees
36
Market Cap
2.69M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionHCWB News
- 2 days ago - HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors - GlobeNewsWire
- 4 weeks ago - HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results - GlobeNewsWire
- 6 weeks ago - HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic - GlobeNewsWire
- 6 weeks ago - HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances - GlobeNewsWire
- 2 months ago - HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter - GlobeNewsWire
- 2 months ago - HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules - GlobeNewsWire
- 2 months ago - HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune - GlobeNewsWire
- 5 months ago - HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease - GlobeNewsWire